Cicas IP LLC v. Stryker Corporation: Surgical Navigation Patent Dispute Ends in Dismissal
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Cicas IP LLC v. Stryker Corporation |
| Numéro de dossier | 2:23-cv-00295 (E.D. Tex.) |
| Tribunal | Tribunal fédéral de première instance pour le district Est du Texas |
| Durée | June 2023 – March 2024 9 months |
| Résultat | Rejeté avec préjudice |
| Brevets en cause | |
| Produits incriminés | Stryker’s endoscopic targeting and surgical navigation systems |
Aperçu du dossier
Les parties
⚖️ Demandeur
A non-practicing entity (NPE) asserting patent rights in the medical imaging and surgical navigation technology domain.
🛡️ Défendeur
A Fortune 500 global medical device company. Co-defendant Scopis GmbH specializes in augmented reality surgical navigation.
Le brevet en cause
This case involved U.S. Patent No. 6,850,794 B2, covering an endoscopic targeting method and system. This technology enables precise instrument navigation during minimally invasive surgical procedures using endoscopic imaging guidance.
- • US 6,850,794 B2 — Endoscopic targeting method and system (Application No. US09/957477)
Designing a surgical navigation product?
Check if your medical device design might infringe this or related patents before launch.
Le verdict et l'analyse juridique
Résultat
On March 21, 2024, the court accepted the parties’ Joint Stipulation of Dismissal, ordering all claims and causes of action dismissed with prejudice. No damages figure was publicly disclosed, and no injunctive relief was granted. This dismissal “with prejudice” means Cicas IP cannot reassert these specific claims against these defendants in future litigation.
Principales questions juridiques
Because the matter resolved before any substantive rulings on claim construction, validity, or infringement, there is no public judicial analysis of how the ‘794 patent claims read on Stryker’s accused endoscopic targeting systems. The joint nature of the dismissal stipulation, combined with the “with prejudice” designation and each-party-bears-own-fees structure, is a signature pattern in confidential patent license settlements in the Eastern District of Texas.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in surgical navigation design. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View all related patents in this medical device technology space
- See which companies are most active in surgical navigation patents
- Understand patent claim patterns in endoscopic targeting
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit médical.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Endoscopic targeting methods
1 Brevet revendiqué
But from a broader patent family
Importance procédurale
Illustrates early-stage resolution tactics
✅ Points clés à retenir
Dismissal with prejudice following joint stipulation is a strong indicator of confidential licensing resolution — not necessarily plaintiff or defendant “victory.”
Rechercher la jurisprudence connexe →The Eastern District of Texas continues to be a high-activity venue for medical device NPE assertions, often leading to rapid pre-trial resolutions.
Explorer les précédents →Foire aux questions
U.S. Patent No. 6,850,794 B2 (application no. US09/957477), covering an endoscopic targeting method and system, was the sole patent asserted in this case.
The parties filed a Joint Stipulation of Dismissal representing the matter had been resolved, which the court accepted. “With prejudice” means the claims cannot be re-filed against these defendants. No public explanation of the resolution terms was provided.
It reinforces that legacy endoscopic and surgical navigation patents remain viable assertion vehicles against modern medical device companies, and that pre-trial resolutions are common in this space — particularly in the Eastern District of Texas.
Companies in the medical device and surgical navigation space can protect themselves by conducting early and comprehensive Freedom-to-Operate (FTO) analyses, especially for technologies with long development cycles. Thorough IP due diligence during M&A, proactive patent landscaping, and strategic patent filing are also crucial. PatSnap Eureka’s tools help identify potentially blocking patents and navigate complex IP landscapes.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- United States Patent and Trademark Office — U.S. Patent No. 6,850,794 B2
- PACER – Eastern District of Texas Case No. 2:23-cv-00295
- U.S. District Court for the Eastern District of Texas Local Patent Rules
- PatSnap — IP Intelligence Solutions for Medical Device Companies
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.